US Patent Issued to Regeneron Pharmaceuticals on May 12 for "Method of reducing serum amyloid a (SAA) protein levels in a patient by administering an interleukin-33 (IL-33) antibody" (American, French Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,624,114, issued on May 12, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Method of reducing serum amyloid a (SAA) protein levels in a patient by administering an interleukin-33 (IL-33) antibody" was invented by Jamie M. Orengo (Cortlandt Manor, N.Y.), Jeanne Allinne (Paris), Andrew J. Murphy (Croton-on-Hudson, N.Y.) and George D. Yancopoulos (Yorktown Heights, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of ...